TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01752153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferrioxamine, Legalon® (Silymarin)
Description: Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon)
Study: NCT02553785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revivent TC
Study: NCT03639805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy program MUSIC CARE® + standard care
Description: Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care of vaso-occlusive crises
Description: administration of standard care only
Study: NCT01947426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA Supplementation
Description: mothers consuming 400 mg of DHA/day and their neonates

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (milk without DHA)
Description: mothers consuming placebo product and their neonates
Study: NCT04346212

Intervention type: DIAGNOSTIC_TEST
Intervention: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)
Description: We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
Study: NCT04476121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF application
Description: PRF application into post-operative wound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nipas application
Description: Nipas application into post-operative wound.
Study: NCT00602290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were \> 2 until treatment completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were \> 2 until treatment completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (MPH)
Description: MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (MPH)
Description: MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
Study: NCT03191864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Study: NCT02267135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
Study: NCT01527487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m2 IV (Days 1 \& 8), given short (≤15 minute) IV infusion, per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
Study: NCT04182568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel followed by anthracycline and cyclophosphamide
Description: nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel followed by anthracycline and cyclophosphamide
Description: Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
Study: NCT02289846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-9179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-9179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-9179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study: NCT02312453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior approach
Description: We adopted the technique as described by Hebbard et al.
Study: NCT03395717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton-Assisted Gait Training
Study: NCT00427206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen (4g/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02823834

Intervention type: DEVICE
Intervention: PROFEMUR® Gladiator Plasma Femoral Stems
Description: THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
Study: NCT04574934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic therapy
Description: Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
Study: NCT03018366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17beta Estradiol
Description: Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal placebo patch
Description: Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
Study: NCT02607852

Intervention type: DEVICE
Group type: OTHER
Intervention: iPads
Description: The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
Study: NCT01093183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT04358068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin (Azithro)
Description: Administered orally
Study: NCT04561024

Intervention type: DIAGNOSTIC_TEST
Intervention: AI model
Description: Deep Learning CNN model

Intervention type: DIAGNOSTIC_TEST
Intervention: AI model
Description: Deep Learning CNN model
Study: NCT04096443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplant (FMT)
Description: Oral fecal microbial transplant capsules
Study: NCT01976468

Intervention type: OTHER
Intervention: SCC metastasis
Description: occurrence of SCC metastasis
Study: NCT03144843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
Study: NCT03053648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure
Description: The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
Study: NCT06318052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The FemTouch delivery system
Description: The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gynomunal gel treatment
Description: hormone/free, vaginal moisturizing gel for women with vaginal dryness
Study: NCT01300299

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (\> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within \<2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
Study: NCT02152553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00751257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 2400mg (1200mg b.i.d., 600mg capsules, p.o.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules
Study: NCT01497886

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hip Hop Stroke educational program
Description: Three one-hour sessions, conducted over three consecutive days

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Education program
Description: The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence).
Study: NCT04103827

Intervention type: OTHER
Intervention: usability assessment
Description: Usability of Le Qoos will be assessed using a validated usability questionnaire

Intervention type: OTHER
Intervention: usability assessment
Description: Usability of Le Qoos will be assessed using a validated usability questionnaire

Intervention type: OTHER
Intervention: usability assessment
Description: Usability of Le Qoos will be assessed using a validated usability questionnaire
Study: NCT02368743

Intervention type: DRUG
Intervention: mesalazine
Study: NCT03126565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifeline CareSage Flagging
Description: Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
Study: NCT04351906

Intervention type: DEVICE
Group type: OTHER
Intervention: ECCO2R
Description: ECCO2R integrated into the multiFiltrate device
Study: NCT01443091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of mother's own colostrum
Description: application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: application of sterile water
Description: application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
Study: NCT02973334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ingestion of artificially-sweetened beverages
Description: From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ingestion of sugar-sweetened beverages
Description: From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of water
Description: From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
Study: NCT04621526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine- ketamine
Description: patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine- propofol
Description: patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
Study: NCT02525601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CR cemented
Description: Implantation of Knee Prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CR uncemented
Description: Implantation of Knee Prosthesis
Study: NCT02231281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cART(TDF/AZT+3TC+LPV/r)
Description: Standard antiretroviral therapy for HIV infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cART(TDF/AZT+3TC+LPV/r)
Description: Standard antiretroviral therapy for HIV infection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTL infusion
Description: cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
Study: NCT01200732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil, placebo
Description: 20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil, placebo
Description: 20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
Study: NCT00993759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3804-250A
Description: 3.2 ml applied topically after hand washing and at least every 3 hours while awake.
Study: NCT00371644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Therapy
Description: PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.